✨ Onyx Summary MassBio praised the enactment of the FY2026 appropriations bill, which includes a $400 million funding increase for the National Institutes of Health along with provisions advancing PBM reform and reauthorizing the Rare Pediatric Disease Priority Review Voucher program. The measure reinforces bipartisan support for federal biomedical research, which
✨ Onyx Summary Guardant Health announced its participation in several upcoming investor conferences in February and March, including events hosted by BTIG, TD Cowen, Leerink Partners, and Barclays. Management will conduct one-on-one meetings and fireside chats, with live and archived webcasts available through the company’s investor website. PALO ALTO, Calif.
✨ Onyx Summary Cellares announced a collaboration with Stanford Medicine to automate manufacturing and release testing for gene-edited hematopoietic stem cell therapies, extending its automation platforms beyond T cell therapies into a new cell modality. The effort aims to establish a standardized, scalable manufacturing foundation that can reduce variability and accelerate
✨ Onyx Summary Foghorn Therapeutics announced that management will present at the Guggenheim Emerging Outlook: Biotech Summit on February 11, 2026, with CEO Adrian Gottschalk delivering a webcasted presentation and participating in one-on-one meetings. The appearance supports investor engagement as the company advances its oncology-focused pipeline built on its Gene Traffic
✨ Onyx Summary Alzheon reported new plasma biomarker analyses from its Phase 3 APOLLOE4 and Phase 2 studies showing that valiltramiprosate (ALZ-801) produced early and sustained reductions in p-tau217, correlating with cognitive, functional, and neuroimaging benefits in genetically defined Alzheimer’s patients. The data biologically validate the drug’s mechanism and
✨ Onyx Summary Kyverna Therapeutics appointed Mayo Pujols as Chief Technology Officer effective February 9, 2026, as the company prepares for a potential transition to commercial stage and a planned biologics license application for miv-cel in stiff person syndrome. The leadership change strengthens Kyverna’s manufacturing and technical operations capabilities as
SAN DIEGO, Feb. 2, 2026 – Avidity Biosciences, Inc. ("Avidity") (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates ("AOCs™") to profoundly improve people's lives, today announced that its board of directors has designated the close
✨ Onyx Summary ImmunityBio announced the launch of ResQ215B, a Phase 2 outpatient study evaluating a chemotherapy- and lymphodepletion-free combination immunotherapy for patients with indolent B-cell non-Hodgkin lymphoma, including Waldenström’s Macroglobulinemia. Building on prior Phase 1 data showing durable responses with CD19 CAR-NK cells plus rituximab, the study adds ANKTIVA
✨ Onyx Summary Guardant Health and collaborators reported results from the largest study to date showing that postoperative circulating tumor DNA detection with Guardant Reveal more accurately predicts recurrence and overall survival than standard staging in patients with resected stage III colon cancer. Published in the Journal of Clinical Oncology, the
✨ Onyx Summary Perspective Therapeutics priced an underwritten public offering of common stock and pre-funded warrants expected to raise approximately $175 million in gross proceeds. The financing strengthens the company’s balance sheet to advance its radiopharmaceutical pipeline, expand manufacturing capabilities, and support general corporate purposes. SEATTLE, Feb. 02, 2026 – Perspective
✨ Onyx Summary Belite Bio announced it will participate in the Asia-Pacific Academy of Ophthalmology Congress 2026 in Hong Kong, presenting previously disclosed topline Phase 3 DRAGON study results and patient case reports for tinlarebant in adolescent Stargardt disease type 1. The presentations reinforce Belite Bio’s clinical progress and visibility
✨ Onyx Summary Guardant Health announced it will report fourth-quarter and full-year 2025 financial results after market close on February 19, 2026, followed by a webcasted conference call with management later that afternoon. PALO ALTO, Calif.– Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report
✨ Onyx Summary Lexicon Pharmaceuticals commenced an underwritten public offering of common stock, with Jefferies and Piper Sandler acting as joint book-running managers, alongside a concurrent private placement with an affiliate of Invus under its preemptive rights. The financing is intended to support continued research and development of Lexicon’s pipeline
✨ Onyx Summary Opentrons Labworks promoted James Atwood to Chief Executive Officer, formalizing his leadership after overseeing growth to more than 10,000 robotic systems deployed across academic and biopharma laboratories worldwide. The move reinforces Opentrons’ strategy to connect AI-driven discovery with physical lab execution, highlighted by its role as an
✨ Onyx Summary Cellares raised $257 million in a Series D financing co-led by investment funds managed by BlackRock and Eclipse, bringing total capital to $612 million to fund the global rollout of automated IDMO Smart Factories and support commercial-scale cell therapy manufacturing beginning in 2027. The financing positions Cellares to
✨ Onyx Summary nChroma Bio has dosed the first patient in a Phase 1/2 clinical trial of CRMA-1001, an investigational epigenetic silencer aimed at achieving a functional cure for chronic hepatitis B, and secured additional clinical trial approvals in New Zealand and the UK. The milestone marks the company’s
